S. 527 · 119th Congress · Commerce
Prescription Pricing for the People Act of 2025
Requires the FTC to report on anticompetitive practices in pharmaceutical supply chains and pharmacy benefit manager conduct. AI-read
What it does
This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.
The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.
The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.
Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.
Summary by the Congressional Research Service, Feb 11, 2025 (Introduced in Senate). CRS summarizes bills impartially; it does not take positions.
Roll call votes
No recorded roll call votes on this bill. Most bills never get one; many pass by voice vote or unanimous consent, or stay in committee.
Latest action
Apr 10, 2025 · Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.